NL-OMON42675已完成不适用
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed) - ProCaMolMed
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Retrospective cohort
- •- Participants of Group 1 and/or 2 in PCMM.
- •- Obtained informed consent in PCMM.;Prospective cohort
- •- Men >= 18 years.
- •- Planned to undergo prostate biopsies according to standard practice.
- •- Signed informed consent.
排除标准
- •Prospective cohort
- •- Documented acute prostatitis or urinary tract infections within 8 weeks prior to inclusion.
研究者
相似试验
已完成
不适用
Prostate Cancer Molecular Medicineprostate carcinoma1003859710036958Prostate cancerNL-OMON39774Erasmus MC, Universitair Medisch Centrum Rotterdam496
招募中
不适用
Prostate Cancer Molecular Medicine (PCMM).Prostate cancer / prostaatkankerNL-OMON27495Erasmus MC, NKI-AvL, UMCG, UMC400
进行中（未招募）
1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Metastatic prostate cancerEUCTR2022-003788-13-FIHeikki Minn40
进行中（未招募）
1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Prostate cancerCTIS2024-511104-16-00Turku University Hospital40
已完成
不适用
Transmurale zorg Prostaatkanker, van diagnose tot en met nazorgProstate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.NL-OMON22953Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer200